B-MOF自我增强的pullulan/chitosan水凝用于糖尿病伤口管理:抗菌,抗炎和促愈性质
Yaowen Liang1, Jiaming Deng2, Jinrong Zhang1
1Yunfu People's Hospital, Central Laboratory of Yunfu People's Hospital, Yunfu City, Guangdong Province, PR China.
International journal of biological macromolecules
|October 30, 2025
概括
一种新型的多糖水凝通过减少炎症,抗击细菌和促进愈合,有效治疗糖尿病伤口. 这种先进的伤口包裹整合了药物输送和微环境调制,用于全面的糖尿病伤口管理.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 伤口治愈研究研究 伤口治愈研究
背景情况:
- 糖尿病伤口治疗面临着慢性炎症,细菌感染和血管新生不良的挑战.
- 单模疗法对于有效的糖尿病伤口管理是不够的.
- 开发多功能策略对于全面的糖尿病伤口护理至关重要.
研究的目的:
- 开发一种多糖体水凝系统,用于糖尿病伤口治疗中的综合药物输送和微环境重塑.
- 为了创建一个多功能水凝 (P1K3@B-MOF) 结合酸B (Sal B) 装载的化物伊米达酸框架-8 (B-MOF).
- 在糖尿病伤口模型中评估P1K3@B-MOF水凝的治疗疗效.
主要方法:
- 制造P1K3@B-MOF水凝,使用氧化普卢兰,四分化奇托和Sal B-载荷的B-MOF通过离子和键.
- 评估水凝的特性,包括生物相容性,抗菌活性 (>90%的抑制) 和自我愈合能力.
- 在糖尿病大鼠的全厚皮肤缺陷模型中的体内评估,监测炎症,血管生成,再上皮化和伤口关闭.
主要成果:
- P1K3@B-MOF水凝显示出优异的生物相容性,广泛的抗菌活性和自我愈合特性.
- 控制释放的Sal B和Zn2+促进了细胞迁移,血管新生和M2巨细胞的两极分化 (抗炎性表型).
- 在糖尿病老鼠中,水凝显著降低了炎症,增强了颗粒组织形成,新血管化,重新表皮化和原重塑,同时最大限度地减少了痕形成,从而加速了伤口的关闭.
结论:
- 开发的基于多糖的水凝系统为糖尿病伤口管理提供了一个有前途的治疗策略.
- P1K3@B-MOF水凝的药物释放控制和多功能协同效应解决了糖尿病伤口愈合的关键挑战.
- 这种创新方法提供了一种全面的解决方案,可以加速伤口关闭并改善糖尿病患者的组织再生.
相关概念视频
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...